Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care.
We are a publicly traded (NASDAQ: AERI), ophthalmic pharmaceutical company focused on the discovery, development and commercialisation of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye.
Glaucoma is one of the largest segments in the global ophthalmic market, exceeding $5b in 2016 in the United States, Europe and Japan. Glaucoma is a progressive disease in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, resulting in irreversible vision loss and potentially blindness. Additionally, glaucoma is a highly individualised disease and there is no direct correlation of the level of IOP at diagnosis with damage to the optic nerve.
Our first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, was approved by the United States Food & Drug Administration (FDA) in December 2017 for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Our second product, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, is a fixed dose combination of Rhopressa® and latanoprost, a widely prescribed prostaglandin analogue (PGA). We expect to file our NDA for Roclatan™ in the second quarter of 2018.
If approved, we believe Roclatan™ has the potential to be the most efficacious therapy for lowering of elevated IOP in the marketplace.
Aerie currently employs 300+ located in the US and EU with plans to grow to 370 by end of 2018 and beyond in 2019. Headquartered Raleigh/Durham - NC we are also located in Irvine – CA, Bedminster - NJ, Dublin & Malta. We are building our broader organisation in readiness for the commercialisation of our products, and the supply of same via our first manufacturing facility located in Athlone, Ireland.
Aerie have acquired the 2,650m2 IDA Advanced Technology Building in Athlone and will embark on an initial investment of $60m. A fast track start-up, our new sterile filling plant will be designed, constructed and validated for the global supply of our ophthalmic products with a target first regulatory approval & commercialization in early 2020. The plant will include end to end operations – compounding, sterile filling, and packaging with all support capabilities (QC labs, warehousing, etc.).